Interesting Life Journey of a Type 1 Diabetes Individual from the Era of Injectable Insulins to the Hybrid Closed-Loop Insulin Pump

Abstract Continuous subcutaneous insulin infusion (CSII) pump has shown good outcomes in individuals with diabetes. An individual with type 1 diabetes (T1D) was diagnosed in 1996 at the age of 14 years with GAD-positive and absent C Peptide reserves confirming the diagnosis. Initially, the individua...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of diabetology Ročník 15; číslo 4; s. 443 - 446
Hlavní autoři: Damle, Varun Anil, Amutha, Anandakumar, Lovelena, Munnavar, Mohan, Viswanathan
Médium: Journal Article
Jazyk:angličtina
Vydáno: India Wolters Kluwer - Medknow 01.10.2024
Wolters Kluwer Medknow Publications
Vydání:3
Témata:
Case Report
hybrid closed-loop insulin pump; treatment; type 1 diabetes
treatment
Hybrid closed-loop insulin pump
type 1 diabetes
ISSN:2543-3288, 2078-7685
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Abstract Continuous subcutaneous insulin infusion (CSII) pump has shown good outcomes in individuals with diabetes. An individual with type 1 diabetes (T1D) was diagnosed in 1996 at the age of 14 years with GAD-positive and absent C Peptide reserves confirming the diagnosis. Initially, the individual was started with the conventional treatment for T1D consisting of multiple insulin injections per day, however, with this treatment, there was a wide fluctuation in the blood sugar levels with frequent hyperglycemic and hypoglycemic episodes, and could not achieve strict HbA1c control. In 2019, the treatment was switched to a 620G CSII pump, the fluctuations in blood sugar levels were reduced, but still, there were occasional hyperglycemic and hypoglycemic episodes failing to achieve the target HbA1c control. In 2022, again the treatment was changed to the latest 780G CSII pump termed the artificial pancreas which helped the person with T1D to achieve strict blood sugar level control and excellent 'Time in Range' with no hyperglycemic and hypoglycemic episodes and a better quality of life.
ISSN:2543-3288
2078-7685
DOI:10.4103/jod.jod_132_24